VanessaLynnDickeyMD

Hematology • Torrance, CA

Clotting Disorder, Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Oncology Chair; Providence Little Company of Medicine

Join to view full profile

Dr. Dickey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dickey's full profile

Already have an account?

Office
Hunt Cancer Center
3285 Skypark Drive
Torrance, CA 90505
Phone+1 310-750-3300

Fax+1 310-750-3300

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2002 - 2003
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2000 - 2002
Santa Barbara Cottage HospitalResidency, Internal Medicine, 1997 - 2000
Eastern Virginia Medical SchoolClass of 1997

Certifications & Licensure

CA State Medical License 2003 - 2027
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Start of enrollment: 2009 Oct 01
Completed
Phase 2
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Start of enrollment: 2013 Apr 01
Terminated
Phase 3
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) Start of enrollment: 2014 Sep 30
Completed
Phase 3
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label Start of enrollment: 2014 Nov 01
Terminated
Phase 2
Join now to see all

Press Mentions

Holistic Help for Serious IllnessAugust 3rd, 2021